12.02

1.40% -0.17

Perspective Therapeutics Inc (CATX)

Overview News Price History Discussions Forecast Stock Split

Perspective Therapeutics Inc stock is traded at $12.02, with a volume of 181.38K. It is down -1.40% in the last 24 hours and down -9.97% over the past month. Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Previous Close:

$12.19

Open:

$12.15

24h Volume:

181.38K

Relative Volume:

0.22

Market Cap:

$825.31M

Revenue:

$6.96M

Net Income/Loss:

$-46.51M

P/E Ratio:

-147.30

EPS:

-0.0816

Net Cash Flow:

$-37.99M

1W Performance:

+1.26%

1M Performance:

-9.97%

6M Performance:

-33.59%

1Y Performance:

+339.63%

1-Day Range:

$11.95

$12.34

1-Week Range:

$11.40

$12.90

52-Week Range:

$2.201

$19.05

Perspective Therapeutics Inc Stock (CATX) Company Profile

Name

Perspective Therapeutics Inc

Sector

Healthcare (1181)

Industry

Medical Devices (155)

Phone

509-375-1202

Address

350 Hills Street, Suite 106, Richland

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CATX's Discussions on Twitter

Perspective Therapeutics Inc Stock (CATX) Latest News

03:45 AM

Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

03:45 AM

Nov 03, 2024

Perspective Therapeutics targeting tumors - The Gazette

Nov 03, 2024

Nov 01, 2024

Hills Bank & Trust Co Takes $13.72 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat

Nov 01, 2024

Oct 31, 2024

Perspective Therapeutics management to meet virtually with Cantor Fitzgerald - Nasdaq

Oct 31, 2024

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024

Oct 30, 2024

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga

Oct 30, 2024

Oct 29, 2024

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November - The Manila Times

Oct 29, 2024

Oct 28, 2024

Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock's lead-212 edge - Investing.com India

Oct 28, 2024

Oct 25, 2024

1,602,283 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Purchased by Nicholson Wealth Management Group LLC - MarketBeat

Oct 25, 2024

Oct 24, 2024

Perspective Therapeutics (NYSE:CATX) Shares Gap UpStill a Buy? - MarketBeat

Oct 24, 2024

Perspective Therapeutics initiated with a Buy at UBS - TipRanks

Oct 24, 2024

Perspective Therapeutics (NYSE:CATX) Given Outperform Rating at Wedbush - MarketBeat

Oct 24, 2024

Market undervaluing Perspective Therapeutics stock amid upcoming trial data, says UBS - Investing.com

Oct 24, 2024

Perspective Therapeutics (NYSE:CATX) Now Covered by UBS Group - MarketBeat

Oct 24, 2024

Oct 23, 2024

Perspective Therapeutics presents updates at 37th Annual Congress of EANM - TipRanks

Oct 23, 2024

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine - The Manila Times

Oct 23, 2024

Immunodeficiency Therapeutics Market Analysis by Industry - openPR

Oct 23, 2024

Oct 22, 2024

Capricor Therapeutics (NASDAQ:CAPR) shareholder returns have been enviable, earning 685% in 5 years - Simply Wall St

Oct 22, 2024

Oppenheimer maintains outperform rating on CATX shares amid new data - Investing.com India

Oct 22, 2024

Oct 21, 2024

Siemens Healthineers Gets FDA Clearance for Alzheimer’s Disease Analysis Features - Imaging Technology News

Oct 21, 2024

Oct 20, 2024

The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Oct 20, 2024

Oct 16, 2024